Skip to main content
Evidence Snapshot

NCI-H720

CHEMBL2366105 CELL-LINE Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:09:58Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2366105
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats NCI-H720 as ChEMBL target CHEMBL2366105. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
NCI-H720
CELL-LINE · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2366105
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why NCI-H720 matters

As of 2026-09-13

NCI-H720 is reviewed as NCI-H720; the current evidence base includes 24 approved drugs, 119 compounds, and 1 assay, with lead potency reaching pChEMBL 9.2.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 24 approved drugs, 119 compounds, and 1 assay for this target. The dominant activity type is IC50. CHEMBL3545252 is the current potency anchor at pChEMBL 9.2.

Use CHEMBL3545252 as the tractability anchor when discussing potency (pChEMBL 9.2).

Activity source · ChEMBL 36 via Core Engine
24 approved pChEMBL 9.2
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why NCI-H720 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

119
Total Compounds
1
Total Assays
24
Approved Drugs
IC50: 120.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL3545252
 9.2 IC50 Approved
No preferred name
CHEMBL1879463
 8.4 IC50 Clinical
No preferred name
CHEMBL159
 8.2 IC50 Approved
No preferred name
CHEMBL1201182
 8.0 IC50 Approved
No preferred name
CHEMBL1090090
 7.8 IC50 Clinical

Approved Drugs

Structure Compound First Approval
AFATINIB
CHEMBL1173655
 2013
TEMSIROLIMUS
CHEMBL1201182
 2007
VORINOSTAT
CHEMBL98
 2006
GEFITINIB
CHEMBL939
 2003
SIROLIMUS
CHEMBL413
 1999
DOCETAXEL
CHEMBL3545252
 1995
VINBLASTINE
CHEMBL159
 1965
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:09:58Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2366105